Facebook

EU-India Free Trade Agreement: What future for patients in developing countries?

ALDE Group
&
European Parliament Working Group on Innovation, Access to Medicines and Poverty-Related Diseases

HEARING

EU-India Free Trade Agreement: What future for patients in developing countries?

Hosted by MEP Niccolò Rinaldi and MEP Fiona Hall

European Parliament, Brussels
Room PHS4B001
10th February 14,30-18,00

The European Union is pushing for India to accept intellectual property provisions in the free trade agreement (FTA) under negotiation; these provisions, if accepted, will considerably restrict India’s domestic generic production of medicines. Moreover, the consequences on access to medicines will be felt far beyond the borders of India. As the source of the overwhelming majority of the medicines used in AIDS programs in developing countries and as a key source of medicines for other diseases, India’s role as ‘pharmacy of the developing world’ is effectively under threat, and the health of patients all over the developing world hangs in the balance.

Related Documents

Summary Notes from the Hearing

Presentations

Carlos Correa (University of Buenos Aires/South Centre)

Test data protection, TRIPS requirements & TRIPS-plus provision (PPT)

Dr. Tido von Schoen-Angerer (MSF Access Campaign)

EU-India Free Trade Agreement: What future for patients in developing countries

Katrien Vervoort (Oxfam-Solidariteit)

Data Exclusivity and Access to Medicines - Empirical Evidence

 

Page updated: 10 February 2011
↑ To top